Last reviewed · How we verify
Clopidogrel active metabolite
Clopidogrel active metabolite is a P2Y12 receptor antagonist / Antiplatelet agent Small molecule drug developed by University of Florida. It is currently FDA-approved for Acute coronary syndrome, Percutaneous coronary intervention with stent placement, Stroke prevention in patients with recent myocardial infarction or stroke. Also known as: Plavix.
Clopidogrel active metabolite irreversibly inhibits platelet P2Y12 adenosine diphosphate receptors, preventing platelet aggregation and thrombus formation.
Clopidogrel active metabolite irreversibly inhibits platelet P2Y12 adenosine diphosphate receptors, preventing platelet aggregation and thrombus formation. Used for Acute coronary syndrome, Percutaneous coronary intervention with stent placement, Stroke prevention in patients with recent myocardial infarction or stroke.
At a glance
| Generic name | Clopidogrel active metabolite |
|---|---|
| Also known as | Plavix |
| Sponsor | University of Florida |
| Drug class | P2Y12 receptor antagonist / Antiplatelet agent |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clopidogrel is a prodrug that requires hepatic metabolism to generate its active thiol metabolite, which then binds covalently to the P2Y12 receptor on platelet surfaces. This binding blocks ADP-induced platelet activation and aggregation, reducing the risk of thrombotic events. The active metabolite is responsible for the antiplatelet efficacy of clopidogrel in cardiovascular disease.
Approved indications
- Acute coronary syndrome
- Percutaneous coronary intervention with stent placement
- Stroke prevention in patients with recent myocardial infarction or stroke
Common side effects
- Bleeding
- Dyspnea
- Chest pain
- Rash
Key clinical trials
- A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects (PHASE1)
- Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus (PHASE4)
- Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome
- Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients (PHASE4)
- A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel (PHASE1)
- Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant (PHASE2)
- Effects of Clopidogrel and Clarithromycin on the Oral Disposition of Sibutramine in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clopidogrel active metabolite CI brief — competitive landscape report
- Clopidogrel active metabolite updates RSS · CI watch RSS
- University of Florida portfolio CI
Frequently asked questions about Clopidogrel active metabolite
What is Clopidogrel active metabolite?
How does Clopidogrel active metabolite work?
What is Clopidogrel active metabolite used for?
Who makes Clopidogrel active metabolite?
Is Clopidogrel active metabolite also known as anything else?
What drug class is Clopidogrel active metabolite in?
What development phase is Clopidogrel active metabolite in?
What are the side effects of Clopidogrel active metabolite?
What does Clopidogrel active metabolite target?
Related
- Drug class: All P2Y12 receptor antagonist / Antiplatelet agent drugs
- Target: All drugs targeting P2Y12 receptor
- Manufacturer: University of Florida — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome
- Indication: Drugs for Percutaneous coronary intervention with stent placement
- Indication: Drugs for Stroke prevention in patients with recent myocardial infarction or stroke
- Also known as: Plavix
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing